Oxford Asset Management’s Plus Therapeutics PSTV Stock Holding History

Oxford Asset Management’s Portfolio PSTV Stock Details PSTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-55	Closed	-$50K	–	1032
2019 Q4	$50K	Buy	+55	New	+$50.4K	﹤0.01%	1667
2015 Q3	–	Hold	0	–	-$33K	–	705
2015 Q2	–	Hold	0	–	–	–	641

Other funds holding PSTV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Financial Perspectives Minneapolis, Minnesota $411M AUM 26.27% 1-Year Est. Return

Oxford Asset Management's PSTV Position: Q1 2020 in Review

Oxford Asset Management sold out of Plus Therapeutics (PSTV) in Q1 2020, closing a stake of 55 shares — an estimated $50K sold.

Oxford Asset Management first reported a position in PSTV in Q4 2019 and held it in 1 quarter. The position peaked at $50K in Q4 2019. 5 funds tracked by Wall St. Rank hold PSTV as of Q1 2020.

Oxford Asset Management reported no remaining Plus Therapeutics position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 55 Plus Therapeutics shares in Q1 2020, an estimated $50K.
Oxford Asset Management first reported a position in Plus Therapeutics in Q4 2019 and held it in 1 quarter.
Oxford Asset Management's Plus Therapeutics position peaked at $50K in Q4 2019.
5 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.